硫化缺乏症和心脏代谢HFpEF中的治疗向:证据表明与GLP-1/葡萄糖激素主义有协同效益
Jake E Doiron1, Mahmoud H Elbatreek2, Huijing Xia1
1Department of Pharmacology and Cardiovascular Center, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
JACC. Basic to translational science
|August 7, 2025
概括
硫化 (H2S) 水平在心力衰竭中降低,其中保留喷射分数 (HFpEF). 补充H2S可以改善心脏功能和减少纤维化,这表明HFpEF的新治疗方法.
科学领域:
- 心血管研究研究心血管研究
- 代谢疾病 代谢疾病
- 生物化学 生物化学
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭带来了重大的治疗挑战.
- 硫化 (H2S) 在心血管平衡中起作用.
- 降低H2S生物可用性与各种疾病状态有关.
研究的目的:
- 调查HFpEF患者和相关动物模型中的H2S生物可用性.
- 探索调节HFpEF中的H2S水平的治疗潜力.
主要方法:
- 在HFpEF患者和两种已建立的动物模型 (L-NAME+高脂肪饮食小鼠,ZSF1肥胖大鼠) 中评估了H2S水平.
- 研究了参与H2S代谢的关键酶的表达 (cystathionine-γ-lyase和硫化氧降解酶).
- 在动物研究中使用了cystathionine-γ-lyase淘汰模型和药理学H2S补充剂.
- 研究了H2S补充剂与GLP-1/葡萄糖激素激动剂的协同效应.
主要成果:
- 在HFpEF患者和动物模型中,H2S水平显著降低.
- 降低的H2S与降低的cystathionine-γ-lyase和增加的硫化氨酸氧降解酶表达相关.
- 囊氨酸-γ-酶缺乏症加剧了HFpEF表型.
- 药理学H2S补充剂改善了透析功能,减少了心脏纤维化.
- 补充H2S证明了与GLP-1/葡萄糖激素激动剂的协同作用,改善了HFpEF.
结论:
- 降低H2S生物可用性是HFpEF的一个关键特征.
- 提高H2S生物可用性是对HFpEF的一种有前途的新疗法策略.
- 准H2S代谢可能为治疗HFpEF提供一个新的途径,可能与其他疗法结合使用.
相关概念视频
01:24Glucagon-like Receptor Agonists
419
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
419
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:15Hypoglycemia and Glucagon
337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337
01:22Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
01:23Dipeptidyl Peptidase 4 Inhibitors
260
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
260
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
298
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
298